CMC & REGULATORY
Five CMC bottlenecks to resolve before your IND
Practical considerations for a smoother clinical transition.
Bench To Batch / IRSG · Educational editorial draft · 7 min read
1. Incomplete analytical readiness
Plan method qualification and suitable specifications early enough to support batch release and stability testing.
2. A disconnect between toxicology and clinical supply
Understand differences in process and product quality, and plan a scientific justification or comparability work where needed.
3. Unclear material demand
Include dose, enrollment, losses, testing, reserves and stability samples in your supply forecast.
4. A fragmented documentation package
Assign ownership for manufacturing records, specifications, methods and CMC submission content before execution.
5. An optimistic schedule
Account for raw materials, facility readiness, testing, release, stability commitments and possible regulatory feedback.
Educational planning content, not regulatory advice. Program-specific decisions require qualified quality, manufacturing and regulatory review. Editorial content should be reviewed by your IRSG team before publication.